Suraj G. Bhansali

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors

Birgit Geoerger, Franck Bourdeaut, Steven G. DuBois et al. · Clinical Cancer Research · 2017 · 191 citations

Medicine, Oncology, Pharmacology +17

A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with <i>NRAS</i>-mutant melanoma: Early encouraging clinical activity.

Jeffrey A. Sosman, Muaiad Kittaneh, Martijn P. Lolkema et al. · Journal of Clinical Oncology · 2014 · 128 citations

Life Sciences, Oncology, Pharmacology +17

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study

Marco Gattorno, Laura Obici, Marco Cattalini et al. · Annals of the Rheumatic Diseases · 2016 · 104 citations · Full text

Life Sciences, Immunology, Pharmacology +15

Fluorescence Imaging of the Lymph Node Uptake of Proteins in Mice after Subcutaneous Injection: Molecular Weight Dependence

Fang Wu, Suraj G. Bhansali, Wing‐Cheung Law et al. · Pharmaceutical Research · 2012 · 65 citations

Life Sciences, Immunology, Molecular Biology +17

A comparative study of the effect of oxidative stress on the cytoskeleton in human cortical neurons

Pramod K Allani, Tak Sum, Suraj G. Bhansali et al. · Toxicology and Applied Pharmacology · 2004 · 57 citations

Life Sciences, Neurobiology, Neuroscience +16